View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
September 11, 2018updated 12 Jul 2022 1:12pm

Alkermes expands Phase l trial of ALKS 4230 for advanced solid tumours

Alkermes has expanded its ongoing phase l clinical trial to examine the safety and anti-tumour activity of ALKS 4230 in combination with Keytruda (pembrolizumab) to treat patients with advanced solid tumours.

Alkermes has expanded its ongoing Phase l clinical trial to examine the safety and anti-tumour activity of ALKS 4230 in combination with Keytruda (pembrolizumab) to treat patients with advanced solid tumours.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The trial comprises three stages, including an ongoing monotherapy dose-escalation stage, a proposed monotherapy dose-expansion stage and the newly started combination therapy stage of ALKS 4230 and pembrolizumab.

The trial’s dose-escalation stage intends to identify a maximum-tolerated dose of ALKS 4230 as a monotherapy and to determine the optimal dose range of ALKS 4230 based on immunological-pharmacodynamic effects.

Once this stage is concluded, the monotherapy dose-expansion stage is expected to begin in up to 42 patients with renal cell carcinoma or melanoma.

The combination therapy stage is expected to enrol up to 148 patients with select advanced solid tumours.

It will be conducted independently and simultaneously with the trial’s monotherapy dose-escalation and dose-expansion stages.

“The potential synergies of ALKS 4230 and pembrolizumab on anti-tumour activity may expand treatment options for patients in a variety of tumour settings.”

Furthermore, the combination therapy stage will be evaluated in certain PD-1 approved tumour types in both refractory and treatment-naïve patients, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma, gastric cancer, and others.

Alkermes chief medical officer and Medicines Development and Medical Affairs senior vice-president Craig Hopkinson said: “The emergence of therapeutics targeting the PD-1 pathway has revolutionised the field of oncology, yet there remains significant opportunity to improve the clinical benefit of checkpoint inhibitors for the treatment of solid tumours.

“There is strong scientific rationale supporting the combination of PD-1 pathway inhibition with cytokine therapy such as ALKS 4230 to activate the body’s own immune system to fight cancer, and the potential synergies of ALKS 4230 and pembrolizumab on anti-tumour activity may expand treatment options for patients in a variety of tumour settings.”

Alkermes plans to provide initial data from the dose-escalation cohorts later this year.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena